Europe attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to reach USD 4.32 billion by 2023 from USD 2.93 billion in 2018 growing at a CAGR of 8.10% during the forecast period 2018-2023. Attention deficit hyperactivity disorder (ADHD), is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children (<12 years age) as compared to adolescents. ADHD is also described as hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder. The exact cause for the ADHD is not clear but, expected to be resulted due to genetic factors and environmental influences. ADHD results in improper functioning of nervous system that led to attention deficit and hyperactivity/impulsiveness condition. ADHD is characterized by certain symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The symptoms of attention deficit hyperactivity disorder (ADHD) are controlled by different modalities such as medication (stimulants-amphetamines; non-stimulants-atomoxetine), psychotherapy (behavior therapy, cognitive behavioral therapy), and education/training (parent management training, family training).
Increasing involvements from public organizations, rising public conscious towards the better health conditions, and presence of effective therapeutics for the treatment of ADHD are driving the growth of attention deficit hyperactivity disorder therapeutics market in Europe. However, presence of stringent regulatory guidelines and high cost of the medication for ADHD are expected to restrain the growth of attention deficit hyperactivity disorder therapeutics market in Europe.
Europe attention deficit hyperactivity disorder (ADHD) therapeutics market is segmented based on medication, psychotherapy, and education or training. Medication involves stimulants and non-stimulants. Medication by stimulants comprises of amphetamines, methylphenidate, dextroamphetamine, and dexmethylphenidate, whereas medication by non-stimulants comprises of atomoxetine, bupropion, and guanfacine. Psychotherapy involves behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy. Education or training involves parent management training, social skills training, and school-based interventions.
On the basis of geographical areas, Europe attention deficit hyperactivity disorder (ADHD) therapeutics market is segmented as U.K., Germany, France, Italy, and Spain.
The key players in attention deficit hyperactivity disorder (ADHD) therapeutics market such as, Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.), and Curemark, LLC. (U.S.).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Introduction
5.2 Treatment By Medication
5.2.1 Introduction
5.2.2 Stimulants
5.2.2.1 Introduction
5.2.2.2 Amphetamines
5.2.2.3 Methylphenidate
5.2.2.4 Dextroamphetamine
5.2.2.5 Dexmethylphenidate
5.2.3 Non-Stimulants
5.2.3.1 Introduction
5.2.3.2 Atomoxetine
5.2.3.3 Bupropion
5.2.3.4 Guanfacine
5.3 Treatment By Psychotherapy
5.3.1 Introduction
5.3.2 Behavior Therapy
5.3.3 Cognitive Behavioral Therapy
5.3.4 Interpersonal Psychotherapy
5.3.5 Family Therapy
5.4 Treatment By Education or Training
5.3.1 Introduction
5.3.2 Parent Management Training
5.3.3 Social Skills Training
5.3.4 School-Based Interventions
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Shire plc (Ireland)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Neos Therapeutics, Inc. (U.S.)
8.3 Eli Lilly and Company (U.S.)
8.4 Pfizer Inc. (U.S.)
8.5 Alcobra Ltd. (Israel)
8.6 Supernus Pharmaceuticals, Inc. (U.S.)
8.7 Noven Pharmaceuticals, Inc. (U.S.)
8.8 Novartis AG (Switzerland)
8.9 Johnson & Johnson (U.S.)
8.10 Curemark, LLC., (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
